Physician profile
Tiny E Adams
NPI 1669403218
$5,502.72
in general payments reported to CMS, 2019-2025
21 companies · $887 in 2025
The $887 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,124 · 2022: $1,048 · 2023: $1,301 · 2024: $1,143 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,220 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,219.71 |
| Education | $111.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,053.78 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $1,038.39 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $908.65 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $549.32 | 2021-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $422.45 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $259.24 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $207.01 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $171.32 | 2024-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $163.91 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $155.82 | 2021-2025 | Fanapt |
| Corium, LLC | $133.79 | 2022-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $92.09 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $88.96 | 2021-2024 | Rexulti |
| Gilead Sciences, INC. | $77.62 | 2021-2024 | |
| Indivior INC. | $52.43 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $47.31 | 2021-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $22.04 | 2025 | Pifeltro |
| Supernus Pharmaceuticals, INC. | $16.17 | 2023 | Qelbree |
| Braeburn INC. | $15.23 | 2025 | Brixadi |
| Bayer Healthcare Pharmaceuticals INC. | $14.25 | 2025 | |
| Avanir Pharmaceuticals, INC. | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiny Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.